RÉSUMÉ
OBJECTIVE: The aim of this study was to analyze the temporal trends of HIV epidemiology in Turkey from 2011 to 2016. METHODS: Thirty-four teams from 28 centers at 17 different cities participated in this retrospective study. Participating centers were asked to complete a structured form containing questions about epidemiologic, demographic and clinical characteristics of patients presented with new HIV diagnosis between 2011 and 2016. Demographic data from all centers (complete or partial) were included in the analyses. For the cascade of care analysis, 15 centers that provided full data from 2011 to 2016 were included. Overall and annual distributions of the data were calculated as percentages and the Chi square test was used to determine temporal changes. RESULTS: A total of 2,953 patients between 2011 and 2016 were included. Overall male to female ratio was 5:1 with a significant increase in the number of male cases from 2011 to 2016 (p<0.001). The highest prevalence was among those aged 25-34 years followed by the 35-44 age bracket. The most common reason for HIV testing was illness (35%). While the frequency of sex among men who have sex with men increased from 16% to 30.6% (p<0.001) over the study period, heterosexual intercourse (53%) was found to be the most common transmission route. Overall, 29% of the cases presented with a CD4 count of >500 cells/mm3 while 46.7% presented with a CD4 T cell count of <350 cells/mm3. Among newly diagnosed cases, 79% were retained in care, and all such cases initiated ART with 73% achieving viral suppression after six months of antiretroviral therapy. CONCLUSION: The epidemiologic profile of HIV infected individuals is changing rapidly in Turkey with an increasing trend in the number of newly diagnosed people disclosing themselves as MSM. New diagnoses were mostly at a young age. The late diagnosis was found to be a challenging issue. Despite the unavailability of data for the first 90, Turkey is close to the last two steps of 90-90-90 targets.
Sujet(s)
Infections à VIH/épidémiologie , VIH (Virus de l'Immunodéficience Humaine)/pathogénicité , Hepacivirus/pathogénicité , Virus de l'hépatite B/pathogénicité , Hépatite B/épidémiologie , Hépatite C/épidémiologie , Adolescent , Adulte , Agents antiVIH/usage thérapeutique , Thérapie antirétrovirale hautement active , Numération des lymphocytes CD4 , Lymphocytes T CD4+/effets des médicaments et des substances chimiques , Lymphocytes T CD4+/virologie , Enfant , Enfant d'âge préscolaire , Co-infection , Retard de diagnostic , Femelle , VIH (Virus de l'Immunodéficience Humaine)/effets des médicaments et des substances chimiques , VIH (Virus de l'Immunodéficience Humaine)/physiologie , Infections à VIH/traitement médicamenteux , Infections à VIH/mortalité , Infections à VIH/virologie , Hepacivirus/effets des médicaments et des substances chimiques , Hepacivirus/physiologie , Hépatite B/traitement médicamenteux , Hépatite B/mortalité , Hépatite B/virologie , Virus de l'hépatite B/effets des médicaments et des substances chimiques , Virus de l'hépatite B/physiologie , Hépatite C/traitement médicamenteux , Hépatite C/mortalité , Hépatite C/virologie , Hétérosexualité/statistiques et données numériques , Homosexualité masculine/statistiques et données numériques , Humains , Incidence , Nourrisson , Mâle , Adulte d'âge moyen , Études rétrospectives , Analyse de survie , Turquie/épidémiologie , Charge virale/effets des médicaments et des substances chimiquesRÉSUMÉ
The purpose of this investigation was to compare the efficacy of colistin-based therapies in extremely drug-resistant Acinetobacter spp. bloodstream infections (XDR-ABSI). A retrospective study was conducted in 27 tertiary-care centers from January 2009 to August 2012. The primary end-point was 14-day survival, and the secondary end-points were clinical and microbiological outcomes. Thirty-six and 214 patients [102 (47.7%): colistin-carbapenem (CC), 69 (32.2%): colistin-sulbactam (CS), and 43 (20.1%: tigecycline): colistin with other agent (CO)] received colistin monotherapy and colistin-based combinations, respectively. Rates of complete response/cure and 14-day survival were relatively higher, and microbiological eradication was significantly higher in the combination group. Also, the in-hospital mortality rate was significantly lower in the combination group. No significant difference was found in the clinical (p = 0.97) and microbiological (p = 0.92) outcomes and 14-day survival rates (p = 0.79) between the three combination groups. Neither the timing of initial effective treatment nor the presence of any concomitant infection was significant between the three groups (p > 0.05) and also for 14-day survival (p > 0.05). Higher Pitt bacteremia score (PBS), Acute Physiology and Chronic Health Evaluation II (APACHE II) score, Charlson comorbidity index (CCI), and prolonged hospital and intensive care unit (ICU) stay before XDR-ABSI were significant risk factors for 14-day mortality (p = 0.02, p = 0.0001, p = 0.0001, p = 0.02, and p = 0.01, respectively). In the multivariable analysis, PBS, age, and duration of ICU stay were independent risk factors for 14-day mortality (p < 0.0001, p < 0.0001, and p = 0.001, respectively). Colistin-based combination therapy resulted in significantly higher microbiological eradication rates, relatively higher cure and 14-day survival rates, and lower in-hospital mortality compared to colistin monotherapy. CC, CS, and CO combinations for XDR-ABSI did not reveal significant differences with respect to 14-day survival and clinical or microbiological outcome before and after propensity score matching (PSM). PBS, age, and length of ICU stay were independent risk factors for 14-day mortality.